IPO-bound Aragen Life Sciences plans to invest 1.5 billion rupees ($16.05M) over the next two years to expand drug development and manufacturing. The expansion positions the firm to capture rising outsourcing demand as global pharmaceutical companies diversify supply chains. Managing Director and CEO Manmahesh Kantipudi said the company aims to scale capacity across small molecules and complex biologics ahead of its public debut.
Aragen Plans 1.5 Billion Rupee Expansion
IPO-bound Aragen Life Sciences plans to invest 1.5 billion rupees over the next two years to expand its drug development and manufacturing business. The Indian firm seeks to capture growing outsourcing demand from global pharmaceutical companies and increase its production capacity.
Xurve View
Insights:
Xurve View









